Inhibikase Therapeutics, Inc. (IKT) is a Biotechnology company in the Healthcare sector, currently trading at $1.70. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is IKT = $4 (+135.3% upside).
Valuation: IKT trades at a trailing Price-to-Earnings (P/E) of -3.5 (S&P 500 average ~25).
Net income is $48M (loss), growing at -42.1%/yr. Net profit margin is 0% (thin). Gross margin is -5127.8% (-5222.4 pp trend).
Balance sheet: total debt is $0 against $173M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 21.7 (strong liquidity). Debt-to-assets is 0%. Total assets: $181M.
Analyst outlook: 0 / 2 analysts rate IKT as buy (0%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).
